Fibrates, acting as PPAR-alfa agonists, are commonly utilized to address hypertriglyceridemia, decrease hepatic apolipoprotein C-III (apoC-III) levels, and enhance lipoprotein lipase-mediated lipolysis. Here, APOC3 is linked to hypertriglyceridemia.